Hikma Pharmaceuticals PLC - Asset Resilience Ratio
Hikma Pharmaceuticals PLC (HIK) has an Asset Resilience Ratio of 0.49% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital to net assets of Hikma Pharmaceuticals PLC to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2004–2024)
This chart shows how Hikma Pharmaceuticals PLC's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see HIK asset base.
Liquid Assets Composition Over Time
This chart breaks down Hikma Pharmaceuticals PLC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore HIK long-term investments to assets to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 0% |
| Short-term Investments | GBX25.00 Million | 0.49% |
| Total Liquid Assets | GBX25.00 Million | 0.49% |
Asset Resilience Insights
- Limited Liquidity: Hikma Pharmaceuticals PLC maintains only 0.49% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Hikma Pharmaceuticals PLC Industry Peers by Asset Resilience Ratio
Compare Hikma Pharmaceuticals PLC's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Beijing Tongrentang Co Ltd
SHG:600085 |
Drug Manufacturers - Specialty & Generic | 0.50% |
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Neuland Laboratories Limited
NSE:NEULANDLAB |
Drug Manufacturers - Specialty & Generic | 9.65% |
|
China Resources Double-Crane Pharmaceutical Co Ltd
SHG:600062 |
Drug Manufacturers - Specialty & Generic | 1.18% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.01% |
Annual Asset Resilience Ratio for Hikma Pharmaceuticals PLC (2004–2024)
The table below shows the annual Asset Resilience Ratio data for Hikma Pharmaceuticals PLC.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.49% | GBX25.00 Million ≈ $3.04K |
GBX5.13 Billion ≈ $624.54K |
-0.03pp |
| 2023-12-31 | 0.51% | GBX24.00 Million ≈ $2.92K |
GBX4.68 Billion ≈ $569.42K |
+0.02pp |
| 2022-12-31 | 0.49% | GBX22.00 Million ≈ $2.68K |
GBX4.47 Billion ≈ $543.99K |
-0.06pp |
| 2021-12-31 | 0.55% | GBX24.00 Million ≈ $2.92K |
GBX4.37 Billion ≈ $531.95K |
-0.03pp |
| 2020-12-31 | 0.58% | GBX24.00 Million ≈ $2.92K |
GBX4.13 Billion ≈ $503.11K |
0.00pp |
| 2019-12-31 | 0.59% | GBX23.00 Million ≈ $2.80K |
GBX3.93 Billion ≈ $478.17K |
-0.02pp |
| 2018-12-31 | 0.60% | GBX21.00 Million ≈ $2.56K |
GBX3.50 Billion ≈ $425.48K |
-0.05pp |
| 2017-12-31 | 0.65% | GBX22.00 Million ≈ $2.68K |
GBX3.39 Billion ≈ $412.22K |
+0.19pp |
| 2016-12-31 | 0.46% | GBX20.00 Million ≈ $2.43K |
GBX4.36 Billion ≈ $530.85K |
-0.31pp |
| 2015-12-31 | 0.77% | GBX20.00 Million ≈ $2.43K |
GBX2.60 Billion ≈ $315.98K |
+0.41pp |
| 2014-12-31 | 0.36% | GBX8.00 Million ≈ $973.37 |
GBX2.25 Billion ≈ $273.88K |
-0.01pp |
| 2013-12-31 | 0.36% | GBX7.00 Million ≈ $851.70 |
GBX1.93 Billion ≈ $234.70K |
-0.28pp |
| 2012-12-31 | 0.64% | GBX11.04 Million ≈ $1.34K |
GBX1.73 Billion ≈ $210.50K |
+0.47pp |
| 2011-12-31 | 0.16% | GBX2.60 Million ≈ $315.74 |
GBX1.58 Billion ≈ $191.71K |
-0.16pp |
| 2010-12-31 | 0.32% | GBX3.57 Million ≈ $434.73 |
GBX1.12 Billion ≈ $135.76K |
+0.09pp |
| 2009-12-31 | 0.23% | GBX2.33 Million ≈ $283.98 |
GBX1.02 Billion ≈ $124.44K |
+0.14pp |
| 2008-12-31 | 0.08% | GBX819.00K ≈ $99.65 |
GBX966.46 Million ≈ $117.59K |
-0.54pp |
| 2007-12-31 | 0.63% | GBX5.63 Million ≈ $684.76 |
GBX894.04 Million ≈ $108.78K |
-0.46pp |
| 2006-12-31 | 1.09% | GBX5.34 Million ≈ $649.36 |
GBX488.36 Million ≈ $59.42K |
-0.19pp |
| 2005-12-31 | 1.29% | GBX5.12 Million ≈ $622.96 |
GBX397.96 Million ≈ $48.42K |
-1.83pp |
| 2004-12-31 | 3.12% | GBX7.69 Million ≈ $935.89 |
GBX246.48 Million ≈ $29.99K |
-- |
About Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals. The Generics segment offers oral, respiratory, and other generic and spe… Read more